Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Diabetic Nephropathy | Unmet Need | US/EU | 2017

Login to access report north_east
Contact sales account_box

Patients with type 2 diabetes (T2D) and nephropathy, also known as diabetic nephropathy (DN), are at significant risk of developing end-stage renal disease (ESRD), a condition associated with extreme morbidity/mortality and high cost of care. Current therapies are unable to prevent progressive renal decline once initial DN sets in. As a result, physicians report substantial unmet need for safe and efficacious therapies for this indication. This unmet need represents significant commercial opportunity, one that drug developers have been quick to realize. Understanding the importance of key efficacy, safety and tolerability, and nonclinical attributes to the prescribing decisions for DN will be paramount to developing a successful therapy.

Questions Answered:

  • What are the treatment drivers and goals for DN?
  • What attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for DN?
  • What are the prevailing areas of unmet need and opportunity in DN?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists and nephrologists for a hypothetical new DN drug?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 61 U.S. and 30 European endocrinologists and nephrologists, fielded in January 2017.

Key companies: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, AbbVie, Bayer HealthCare, Janssen

Key drugs: Jardiance, Victoza, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), atrasentan, finerenone, canagliflozin

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
north_east
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
north_east
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…
north_east
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east